Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder.
In self-identified white patients with major depressive disorder (N=126) treated with open-label duloxetine (60-120 mg/d), a significant association of (P=0.020) of a composite risk score (based on SLC6A2 rs5569 [G1287A] AA, HTR1A rs6295 [C(-1019)G] GG, and COMT rs174697 AA/AG) with 17-item Hamilton Depression Rating Scale total score change from baseline to 12 weeks was observed.
Lilly USA, LLC, US Medical Neuroscience Department, Indianapolis, IN 46285, USA. johnphilliphouston@gmail.com
John P
JP
Houston
Wei
W
Zou
Virginie
V
Aris
Bonnie
B
Fijal
Peining
P
Chen
Alexandra N
AN
Heinloth
James
J
Martinez
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000235:genetics; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics*; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D008297:Male; D008957:Models, Genetic; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D044282:Receptor, Serotonin, 5-HT1A / Q000235:genetics; D011795:Surveys and Questionnaires; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome
D000928:Antidepressive Agents; D050484:Norepinephrine Plasma Membrane Transport Proteins; C493227:SLC6A2 protein, human; D013876:Thiophenes; D044282:Receptor, Serotonin, 5-HT1A; D000068736:Duloxetine Hydrochloride; D002394:Catechol O-Methyltransferase